# Yuxian Bai

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yuxian-bai/

## Facts

| Field | Value |
| --- | --- |
| Citations | 19,583 |
| Field | Gastric Cancer Management and Outcomes |
| h-index | 59 |
| i10-index | 148 |
| Last Known Institution | Harbin Medical University |
| OpenAlex ID | https://openalex.org/A5087661837 |
| ORCID iD | https://orcid.org/0000-0002-5004-7523 |
| Works | 349 |

## Researcher papers

Showing 12 of 14.

- [Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study](https://scholariq.org/papers/sintilimab-plus-a-bevacizumab-biosimilar-ibi305-versus-sorafenib-in-unresectable/)
- [Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-in-combination-with-gemcitabine-and-cisplatin-compared-with/)
- [Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction](https://scholariq.org/papers/randomized-double-blind-placebo-controlled-phase-iii-trial-of-apatinib-in/)
- [Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/regorafenib-plus-best-supportive-care-versus-placebo-plus-best-supportive-care/)
- [Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma](https://scholariq.org/papers/effect-of-camrelizumab-vs-placebo-added-to-chemotherapy-on-survival-and/)
- [The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer](https://scholariq.org/papers/the-keynote-811-trial-of-dual-pd-1-and-her2-blockade-in-her2-positive-gastric/)
- [Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-for-her2/)
- [Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study](https://scholariq.org/papers/camrelizumab-versus-investigator-s-choice-of-chemotherapy-as-second-line-therapy/)
- [Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/atezolizumab-plus-bevacizumab-versus-active-surveillance-in-patients-with/)
- [Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial](https://scholariq.org/papers/perioperative-or-postoperative-adjuvant-oxaliplatin-with-s-1-versus-adjuvant/)
- [Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-lenvatinib-plus-placebo-for-advanced/)
- [Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer](https://scholariq.org/papers/sintilimab-plus-chemotherapy-for-unresectable-gastric-or-gastroesophageal/)

## Researcher topics

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Researcher university

- [Harbin Medical University](https://scholariq.org/institutions/harbin-medical-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.